The SOTIO scientific research is focused on expanding the possibilities of treating various types of cancer and autoimmune diseases with the active cellular immunotherapy (ACI) technology as well as inventing and developing new therapeutic approaches, primarily for oncology diseases.

Our scientists closely cooperate with colleagues from SOTIO affiliated or partner companies, Cytune Pharma, NBE-Therapeutics and Max Planck Innovation & Lead Discovery Center, which also develop therapies focused primarily on oncology diseases.

Members of the SOTIO research team actively participate in various worldwide research projects. Outcomes of their work are published in top-tier international medical journals and are presented at prestigious scientific and medical conferences (List of Publications).

The SOTIO research team is also participating in treatment success rate monitoring in individual clinical trials. Using the most advanced detection methods of molecular biology and cancer immunology, the team studies the immune response of individual patients to antineoplastic therapy. The gathered data is valuable in testing therapeutic efficacy in patients and is also published in scientific journals.

Scientific collaborations

Members the SOTIO research team work in collaboration with leading research centers studying cancer immunology, cell apoptosis, immunogenic cell death, and autoimmunity issues. These prominent research centers include:

  • Centre de Recherche des Cordeliers, Paris, Laboratory of Tumor Microenvironment, led by Prof. Catherine Sautes Fridman, Ph.D. and Prof. Herve Fridman, Ph.D.
  • INSERM U892 Centre de Recherche en Cancérologie, Laboratory of Apoptosis and Tumor Progression, Nantes, led by Dr. Pierre Francois Cartron
  • University of Leuven, Belgium, Laboratory of Cell Death Research & Therapy, led by Prof. Patrizia Agostinis, Ph.D., Dr. Abhishek Garg, Ph.D.
  • Rigshospitalet Department, Laboratory of Pathogenesis of Type 1 Diabetes, led by Prof. Karsten Buschhard

We use cookies to give you the best possible experience on our website. More information